Mucosal immunity in human and simian immunodeficiency lentivirus infections

Mucosal Immunology

Volumn 6, Issue 4, 2013, Pages 657-665

  Brenchley, J M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 17; INTERLEUKIN 22; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

ANTIGEN PRESENTING CELL; ANTIVIRAL THERAPY; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; GASTROINTESTINAL TRACT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; LAMINA PROPRIA; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T CELL DEPLETION; TH17 CELL; VIRUS LOAD; VIRUS REPLICATION;

EID: 84879398925     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.15     Document Type: Review

References (114)

1. Giorgi, J.V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859-870 (1999).
2. Salazar-Gonzalez, J.F. et al. Increased immune activation precedes the inflection point ofCD4Tcells and the increased serum virus loadinhuman immunodeficiency virus infection. J. Infect. Dis. 178, 423-430 (1998).
3. Sodora, D.L. et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15, 861-865 (2009).
4. Hunt, P.W. et al. Relationship between Tcell activation and CD4(+) Tcell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008).
5. Barre-Sinoussi, F. et al. Isolation of a T-lympotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
6. Gallo, R.C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865-867 (1983).
7. Kotler, D.P., Gaetz, H.P., Lange, M., Klein, E.B. & Holt, P.R. Enteropathy associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 421-428 (1984).
8. Kapembwa, M.S. et al. Altered small-intestinal permeability associated with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin. Sci. (Lond.) 81, 327-334 (1991).
9. Bjarnason, I. et al. Intestinal inflammation, ileal structure and function in HIV. AIDS 10, 1385-1391 (1996).
10. Sharpstone, D. et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 45, 70-76 (1999).
11. Rodgers, V.D., Fassett, R. & Kagnoff, M.F. Abnormalities in intestinal mucosal T cells in homosexual populations including those with the lymphadenopathy syndrome and acquired immunodeficiency syndrome. Gastroenterology 90, 552-558 (1986).
12. Clayton, F. et al. Rectal mucosal pathology varies with human immunodeficiency virus antigen content anddisease stage.Gastroenterology103, 919-933 (1992).
13. Ullrich, R., Zeitz, M. & Riecken, E.O. Enteric immunologic abnormalities in human immunodeficiency virus infection. Semin. Liver Dis. 12, 167-174 (1992).
14. Kotler, D.P., Reka, S. & Clayton, F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig. Dis. Sci. 38, 1119-1127 (1993).
15. Clayton, F., Snow, G., Reka, S. & Kotler, D.P. Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin. Exp. Immunol. 107, 288-292 (1997).
16. Mattapallil, J.J. et al. Massive infection and loss of memory CD4+ Tcells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005).
17. Li, Q. et al. Peak SIV replication in resting memory CD4+ Tcells depletes gut lamina propria CD4+ T cells. Nature 434, 1148-1152 (2005).
18. Lim, S.G.etal. Lossofmucosal CD4 lymphocytesisanearly featureofHIV infection. Clin. Exp. Immunol. 92, 448-454 (1993).
19. Schneider, T. et al. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 37, 524-529 (1995).
20. Smit-McBride, Z., Mattapallil, J.J., McChesney, M., Ferrick, D. & Dandekar, S. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletionatall stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72, 6646-6656 (1998).
21. Guadalupe, M. et al. Severe CD4 + T-cell depletion ingut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77, 11708-11717 (2003).
22. Shacklett, B.L. et al. Trafficking of human immunodeficiency virus type 1-specific CD8 + Tcellstogut-associated lymphoid tissue during chronic infection. J. Virol. 77, 5621-5631 (2003).
23. Mehandru, S. et al. Primary HIV-1 infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761-770 (2004).
24. Brenchley, J.M. et al. CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749-759 (2004).
25. Picker, L.J. et al. Insufficient production and tissue delivery of CD4 + memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200, 1299-1314 (2004).
26. Schuitemaker, H. et al. Biological phenotype ofhuman immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J. Virol. 66, 1354-1360 (1992).
27. Poles, M.A., Elliott, J., Taing, P., Anton, P.A. & Chen, I.S. Apreponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J. Virol. 75, 8390-8399 (2001).
28. Lapenta, C. et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur. J. Immunol. 29, 1202-1208 (1999).
29. Ye, P. et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194, 519-527 (2001).
30. Brand, S. et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838 (2006).
31. Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534-544 (2008).
32. Aujla, S.J. & Kolls, J.K. IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 87, 451-454 (2009).
33. Brenchley, J.M. et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112, 2826-2835 (2008).
34. Cecchinato, V. et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1, 279-288 (2008).
35. Favre, D.et al. Critical lossofthebalance between Th17 andTregulatorycell populationsinpathogenic SIV infection.PLoS Pathog. 5, e1000295 2009)
36. Gordon, S.N. et al. Disruption of intestinal CD4+ Tcell homeostasis is a key markerof systemic CD4+ Tcell activation inHIV-infected individuals. J. Immunol. 185, 5169-5179 (2010).
37. Klatt, N.R. & Brenchley, J.M. Th17 cell dynamics in HIV infection. Curr. Opin. HIV AIDS 5, 135-140 (2010).
38. Chege, D. et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25, 741-749 (2011).
39. Hunt, P.W. Th17, gut, and HIV: therapeutic implications. Curr. Opin. HIV AIDS 5, 189-193 (2010).
40. Klatt, N.R. et al.Loss of mucosal CD103 + DCs and IL-17 + and IL-22 + lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 5, 646-657 (2012).
41. Xu, H. et al. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol. 5, 658-669 (2012).
42. Reeves, R.K.etal. Gutinflammationand indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 118, 3321-3330 (2011).
43. Nigam, P., Kwa, S., Velu, V. & Amara, R.R. LossofIL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J. Immunol. 186, 745-753 (2010).
44. Boasso, A. et al. HIV inhibits CD4 + T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351-3359 (2007).
45. Manches, O. et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2, 3-dioxygenase-dependent mechanism. J. Clin. Invest. 118, 3431-3439 (2008).
46. Favre, D. et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory Tcells in HIV disease. Sci. Transl. Med. 2, 32r-36r (2010).
47. Estes, J.D. et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 6, e1001052 (2010).
48. Nazli, A. et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6, e1000852 (2010).
49. Mohan, M., Aye, P.P., Borda, J.T., Alvarez, X. & Lackner, A.A. Gastrointestinal disease in simian immunodeficiency virus-infected rhesus macaques is characterized by proinflammatory dysregulation of the interleukin-6-Janus kinase/signal transducer and activator of transcription3 pathway. Am. J. Pathol. 171, 1952-1965 (2007).
50. Li, Q. et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J. Infect. Dis. 197, 420-429 (2008).
51. Barcellini, W. et al. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res. Hum. Retroviruses 12, 325-331 (1996).
52. Ruemmele, F.M. et al. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut 51, 842-848 (2002).
53. Grunfeld, C. & Palladino, M.A. Jr Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv. Intern. Med. 35, 45-71 (1990).
54. Tilg, H. & Kaser, A. Antitumour necrosis factor therapy in Crohn's disease. Expert Opin. Biol. Ther. 2, 715-721 (2002).
55. Tabb, B. et al. Reduced inflammation and lymphoid tissue immuno-pathology in rhesus macaques receiving anti-TNF treatment during primary SIV infection. J. Infect. Dis. 207, 880-892 (2012).
56. WHO-UNAIDS. UNAIDS Report on the Global AIDS Epidemic (2010).
57. Koup, R.A. & Douek, D.C. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb. Perspect. Med. 1, a007252 (2011).
58. Migueles, S.A. & Connors, M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304, 194-201 (2010).
59. Brenchley, J.M. et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol. 1, 49-58 (2008).
60. Ferre, A.L.etal. Mucosal immune responsestoHIV-1inelite controllers: a potential correlate of immune control. Blood 113, 3978-3989 2009).
61. Ferre, A.L. et al. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 84, 11020-11029 (2010).
62. Hansen, S.G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
63. Hansen, S.G. et al. Effector memory Tcell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293-299 (2009).
64. Freel, S.A. et al. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84, 4998-5006 (2010).
65. Scheid, J.F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
66. Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
67. Devito, C. et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165, 5170-5176 (2000).
68. Broliden, K. et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 79, 29-36 (2001).
69. Mestecky, J. et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 20, 972-988 (2004).
70. Brenchley, J.M., Price, D.A. & Douek, D.C. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235-239 (2006).
71. Brenchley, J.M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
72. Klatt, N.R., Funderburg, N.T. & Brenchley, J.M. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 21, 6-13 (2012).
73. Brenchley, J.M. & Douek, D.C. Microbial translocation across theGI tract. Annu. Rev. Immunol. 30, 149-173 (2012).
74. Redd, A.D. et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc. Natl. Acad. Sci. USA 106, 6718-6723 (2009).
75. Redd, A.D. et al. C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation. J. Acquir. Immune Defic. Syndr. 54, 556-559 (2010).
76. Siliciano, J.D. & Siliciano, R.F. Biomarkers of HIV replication. Curr. Opin. HIV AIDS 5, 491-497 (2010).
77. Kuller, L.H. et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5, e203 (2008).
78. Sandler, N.G. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780-790 (2011).
79. Arnsten, J.H. et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21, 617-623 (2007).
80. McCutchan, J.A. et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 21, 1109-1117 (2007).
81. Burdo, T.H. et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J. Infect. Dis. 204, 1227-1236 (2011).
82. Anselmi, A.etal. Immune reconstitutioninhuman immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin. Exp. Immunol. 150, 442-450 (2007).
83. Baroncelli, S. et al. Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with o50copies/ml HIV-1 RNA. J. Clin. Virol. 46, 367-370 (2009).
84. Cassol, E. et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202, 723-733 (2010).
85. Jiang, W. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177-1185 (2009).
86. Marchetti, G. et al. Microbial translocation is associated with sustained failure in CD4 + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22, 2035-2038 (2008).
87. Massanella, M. et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24, 959-968 (2010).
88. Miao, Y.M. et al. Elevated mucosal addressin cell adhesion molecule-1 expression in acquired immunodeficiency syndrome is maintained during antiretroviral therapy by intestinal pathogens and coincides with increased duodenal CD4 T cell densities. J. Infect. Dis. 185, 1043-1050 (2002).
89. Mehandru, S. et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484 (2006).
90. Guadalupe, M. et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80, 8236-8247 (2006).
91. Schacker, T.W. et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 19, 2169-2171 (2005).
92. Estes, J.D. et al. CD4 reconstitution of lymphoid tissues is dependent on earlier initiation of HAART. Conferences on Retroviruses and Opportunistic Infections 14, Los Angeles, CA (2007).
93. Zeng, M. et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121, 998-1008 (2011).
94. Tannock, G.W. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol. 1 (Suppl 1), S15-S18 (2008).
95. Walker, A.W. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11, 7 (2010).
96. Gori, A. et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J. Clin. Microbiol. 46, 757-758 (2008).
97. Wolf, B.W., Wheeler, K.B., Ataya, D.G. & Garleb, K.A. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem. Toxicol. 36, 1085-1094 (1998).
98. Gori, A. et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 4, 554-563 (2011).
99. Ellis, C.L. et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J. Acquir. Immune Defic. Syndr. 57, 363-370 (2011).
100. McKenna, P. et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog. 4, e20 (2008).
101. Handley, S.A. et al. Pathogenic simian immunodeficiency virus infectionis associated with expansion of the enteric virome. Cell 151, 253-266 (2012).
102. Klatt, N.R. et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J. Clin. Invest. 123, 903-907 (2013).
103. Hummelen, R. et al. Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes 2, 80-85 (2011).
104. Hummelen, R. et al. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int. J. Gynaecol. Obstet. 111, 245-248 (2010).
105. Hummelen, R., Vos, A.P., van't Land, B., van Norren, K. & Reid, G. Altered host-microbe interaction in HIV: a target for intervention with pro-and prebiotics. Int. Rev. Immunol. 29, 485-513 (2010).
106. Hummelen, R., Hemsworth, J. & Reid, G. Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression. Nutrients 2, 626-651 (2011).
107. Gonzalez-Hernandez, L.A. et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr. J. 11, 90 (2012).
108. Schunter, M.etal. Randomized pilot trialofasynbiotic dietary supplement in chronic HIV-1 infection. BMC Complement. Altern. Med. 12, 84 (2012).
109. Bibiloni, R. et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100, 1539-1546 (2005).
110. Sood, A. et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 7, 1202-1209 (2009).
111. Zocco, M.A. etal. EfficacyofLactobacillus GGin maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23, 1567-1574 (2006).
112. Gupta, P., Andrew, H., Kirschner, B.S. & Guandalini, S. Islactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 31, 453-457 (2000).
113. Byakwaga, H. et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J. Infect. Dis. 204, 1532-1540 (2011).
114. Pandrea, I. & Apetrei, C. Therapeutic interventions to reduce microbial translocation and immune activation. AIDS, Conference, 25 July 2012, Washington, DC (2012).